Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

Inclusion Criteria: 1. Age ≥ 18 years 2. Laboratory confirmed SARS-CoV-2 infection by nasopharyngeal swab Real time polymerase chain reaction (RT-PCR) 3. Hospitalized for COVID-19 pneumonia 4. Dosing should be within 10 days of symptom start 5. Able and willing to sign informed consent form Exclusion Criteria: 1. History of hypersensitivity to plasma products and/or severe Immunoglobulin A deficiency (\< 7 mg/dL) 2. Requirement of high flow oxygen devices, or non-invasive ventilation or mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) at screening 3. Cardiovascular instability 4. History of thrombo-embolic events 5. Acute renal failure or creatinine \>2 mg/dL or estimated estimated glomerular filtration rate (eGFR) \<30 mL/min 6. History of lung transplantation 7. Major surgery (abdominal and chest) within the last 4 weeks 8. Severe chronic background disease, per investigator's judgement for example, Cirrhosis grade C, Dialysis, cardiac insufficiency (NYHA III), pulmonary disease (FEV1\<50 percent of predicted) etc. 9. Pregnancy or lactation 10. Treatment with plasma units or immunoglobulin preparations within the last 4 weeks 11. Participation in another pharmaceutical interventional clinical study within 4 weeks from screening